

# Michael Bogenschutz

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9350503/publications.pdf>

Version: 2024-02-01

29  
papers

1,458  
citations

643344

15  
h-index

536525

29  
g-index

31  
all docs

31  
docs citations

31  
times ranked

1810  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Prognostic Role of DSM-5 Alcohol Use Disorder Severity and Age of Onset in Treatment Outcome Among Adults Aged 60+. <i>Journal of Addiction Medicine</i> , 2022, 16, 303-309.	1.4	0
2	Stability of Posttreatment Reductions in World Health Organization (WHO) Drinking Risk Levels and Posttreatment Functioning in Older Adults with DSM-5 Alcohol Use Disorder: Secondary Data Analysis of the Elderly Study. <i>Alcoholism: Clinical and Experimental Research</i> , 2021, 45, 638-649.	1.4	4
3	MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. <i>Nature Medicine</i> , 2021, 27, 1025-1033.	15.2	443
4	Residual alcohol use disorder symptoms after treatment predict long-term drinking outcomes in seniors with DSM-5 alcohol use disorder. <i>Alcoholism: Clinical and Experimental Research</i> , 2021, 45, 2396-2405.	1.4	3
5	The Alcohol Dependence Scale and DSM-5 alcohol use disorder: Severity ratings correspond insufficiently in older patients. <i>International Journal of Methods in Psychiatric Research</i> , 2020, 29, e1811.	1.1	7
6	Impact of comorbid mental disorders on outcomes of brief outpatient treatment for DSM-5 alcohol use disorder in older adults. <i>Journal of Substance Abuse Treatment</i> , 2020, 119, 108143.	1.5	1
7	Gabapentin Enacarbil Extended-Release Versus Placebo: A Likely Responder Reanalysis of a Randomized Clinical Trial. <i>Alcoholism: Clinical and Experimental Research</i> , 2020, 44, 1875-1884.	1.4	12
8	Brain activation and subjective anxiety during an anticipatory anxiety task is related to clinical outcome during prazosin treatment for alcohol use disorder. <i>NeuroImage: Clinical</i> , 2020, 26, 102162.	1.4	5
9	Benefit-cost analysis of SBIRT interventions for substance using patients in emergency departments. <i>Journal of Substance Abuse Treatment</i> , 2017, 79, 6-11.	1.5	22
10	Development of a Psychotherapeutic Model for Psilocybin-Assisted Treatment of Alcoholism. <i>Journal of Humanistic Psychology</i> , 2017, 57, 389-414.	1.4	59
11	The efficacy of attention bias modification therapy in cocaine use disorders. <i>American Journal of Drug and Alcohol Abuse</i> , 2016, 42, 459-468.	1.1	28
12	Psychological and neuropsychological assessment of regular hoasca users. <i>Comprehensive Psychiatry</i> , 2016, 71, 95-105.	1.5	70
13	Substance Use Disorders and Schizophrenia. <i>Focus (American Psychiatric Publishing)</i> , 2016, 14, 333-342.	0.4	2
14	The RESCueH Programme: Testing New Non-Pharmacologic Interventions for Alcohol Use Disorders: Rationale and Methods. <i>European Addiction Research</i> , 2016, 22, 306-317.	1.3	19
15	Dose specific effects of olanzapine in the treatment of alcohol dependence. <i>Psychopharmacology</i> , 2015, 232, 1261-1268.	1.5	9
16	Diffusion tensor imaging of white matter networks in individuals with current and remitted alcohol use disorders and comorbid conditions. <i>Psychology of Addictive Behaviors</i> , 2013, 27, 455-465.	1.4	35
17	Studying the Effects of Classic Hallucinogens in the Treatment of Alcoholism: Rationale, Methodology, and Current Research with Psilocybin. <i>Current Drug Abuse Reviews</i> , 2013, 6, 17-29.	3.4	44
18	Predictors of attrition with buprenorphine/naloxone treatment in opioid dependent youth. <i>Addictive Behaviors</i> , 2012, 37, 1046-1053.	1.7	55

#	ARTICLE	IF	CITATIONS
19	Perturbation of the Glutamate-Glutamine System in Alcohol Dependence and Remission. <i>Neuropsychopharmacology</i> , 2011, 36, 1359-1365.	2.8	71
20	Motivational Interviewing and Psychiatry: Use in Addiction Treatment, Risky Drinking and Routine Practice. <i>Focus (American Psychiatric Publishing)</i> , 2011, 9, 42-54.	0.4	7
21	Adolescent Substance Abuse: The Effects of Alcohol and Marijuana on Neuropsychological Performance. <i>Alcoholism: Clinical and Experimental Research</i> , 2011, 35, 39-46.	1.4	102
22	American Indian methamphetamine and other drug use in the Southwestern United States.. <i>Cultural Diversity and Ethnic Minority Psychology</i> , 2011, 17, 366-376.	1.3	20
23	Extended vs Short-term Buprenorphine-Naloxone for Treatment of Opioid-Addicted Youth. <i>JAMA - Journal of the American Medical Association</i> , 2008, 300, 2003-11.	3.8	305
24	Response: Anticipating New Medications. <i>Addiction Science &amp; Clinical Practice</i> , 2008, 4, 36-38.	1.2	1
25	Investigación y práctica en colaboración: la red de ensayos clínicos del NIDA. <i>Revista De Psicología De La Salud</i> , 2006, 18, 11.	0.2	4
26	Use of Oxcarbazepine in Outpatient Alcohol Detoxification. <i>American Journal on Addictions</i> , 2005, 14, 191-192.	1.3	9
27	Treatment of Weight Gain with Fluoxetine in Olanzapine-Treated Schizophrenic Outpatients. <i>Neuropsychopharmacology</i> , 2003, 28, 527-529.	2.8	59
28	Preparing the Next Generation of Psychiatric Researchers: A Story of Obstacles and Optimism. <i>Academic Psychiatry</i> , 2001, 25, 4-8.	0.4	2
29	Examining an Affect Regulation Model of Substance Abuse in Schizophrenia. <i>Journal of Nervous and Mental Disease</i> , 1999, 187, 72-79.	0.5	57